Research · Sep 3, 2026
[DOCS] Doximity Thesis 2026: A Physician-Centric Professional Network Compounds Healthcare-Marketing And Telehealth Workflow Revenue
Doximity Inc. (NYSE: DOCS), headquartered in San Francisco, California, is the leading professional network + workflow-platform for US healthcare professionals — a medical-LinkedIn-equivalent that has grown to ~80%+ verified US physician membership (~1M+ verified members covering most US medical doctors plus selected NPs, PAs, and medical students) and built a diversified-revenue franchise combining pharmaceutical-and-medical-device-marketing + physician-workflow tools + telehealth + physician-staffing. Founded in 2010 by Jeff Tangney (Stanford-MBA, previously co-founder + CEO of Epocrates pioneering mobile-medical-reference app acquired by athenahealth 2013 for $293M) plus Shari Buck and Nate Gross, IPO'd June 2021 at $26/share. Under co-founder + CEO Jeff Tangney (since founding), FY2026 (fiscal year ending March 2026) closes with selected various aggregate revenue ~$620-680M (~12-18% YoY growth reaccelerating from post-COVID-normalization slowdown), adjusted EBITDA ~$330-380M (52-56% margins — among highest in US software/internet), free cash flow ~$280-340M (~45%+ FCF margin), and ~185M shares outstanding. The first deep-dive — the Doximity professional-network + pharmaceutical-marketing platform — covers ~60-65%+ of revenue from the core franchise. The network has built the largest verified US physician professional network with rigorous license-and-credential verification ensuring all members are genuine medical professionals (differentiating from LinkedIn). Members access professional networking, DocNews medical-content distribution, Dialer, GPT, resume tools, CME content. The pharmaceutical-marketing engine generates revenue from major pharma + med-device customers (Pfizer, Merck, BMS, Lilly, Novo Nordisk, AZ, AbbVie, JNJ, Novartis, Roche, Sanofi, GSK, Amgen, Gilead, Vertex, Regeneron, Biogen + Medtronic, Stryker, BSX, EW, Abbott) via sponsored content + native advertising + email marketing + banner display + event sponsorships + research surveys. Targeting precision spans specialty, geography, practice-setting, formulary affiliation, prescribing pattern providing much higher precision than alternatives. 2023-2024 pharma-marketing spend compressed materially due to biotech-funding decline, pharma-cost-rationalization, and Inflation Reduction Act drug-price-negotiation overhang. 2025-2026 modest recovery underway. FY2026 catalyst is pharma-marketing-spend recovery, sponsored-content engagement, new pharma-customer wins, and IRA-overhang resolution. Competes with Sermo (private), Medscape (WebMD), Epocrates, MDLinx, Health Union. The second deep-dive — the physician-workflow tools + telehealth-and-clinical-staffing-platform expansion — covers ~25-30% of revenue from non-marketing products and the meaningful future-growth pillar. Doximity Dialer is the HIPAA-compliant phone + video calling tool widely adopted during COVID-19 for telehealth and stuck as standard physician-workflow post-COVID; generates revenue through employer/health-system enterprise contracts + pharma-sponsored telehealth integrations. Doximity GPT is the AI-powered physician-workflow tool launched 2023-2024 using LLMs for clinical-note summarization, prior-authorization-letter drafting, patient-education-letter writing, denial-appeal letters, referral-letter drafting — adoption has been rapid with strong testimonials about time-savings; monetized via subscription tiers or enterprise contracts; the most exciting growth opportunity given physician-administrative-burden is a well-documented problem. Physician-staffing platform (locum-tenens + selected matching) is smaller but growing. FY2026 catalyst is Doximity GPT adoption + monetization, Dialer engagement, physician-staffing growth, and new workflow-tool introductions. Competes with Veeva (VEEV), IQVIA (IQV), GoodRx (GDRX), Teladoc (TDOC), Hims & Hers (HIMS) + AI-scribe competitors Nuance/Microsoft Healthcare, Abridge, Suki, DeepScribe, Augmedix. Capital position is net-cash and buyback-aggressive: ~$0.7-0.85B+ cash + investments with effectively zero corporate debt, FCF ~$280-340M/yr, no dividend, aggressive buybacks (~$0.5-0.8B+ cumulative over 3 years shrinking from ~190M to ~185M shares), substantial SBC (~$50-100M/yr largely offset by buybacks), Class A public + Class B founder super-voting structure (Jeff Tangney + co-founders concentrated voting). At ~$40-70 per share, equity value ~$7-13B, ~10-19x EV/revenue and ~20-38x EV/adj-EBITDA — premium-growth healthcare-IT multiple. Base case is pharma recovery + GPT monetization + ~15-20% total return; bull case is strong pharma rebound + AI-product acceleration + re-rating to 22-26x EV/revenue + 40-60%+ return; bear case is pharma stays compressed + GPT competitive challenge + de-rating to 7-9x EV/revenue.